Altimmune Stock Today

ALT
 Stock
  

USD 10.28  0.10  0.96%   

Market Performance
0 of 100
Odds Of Distress
Less than 10
Altimmune is selling for under 10.28 as of the 7th of December 2022; that is -0.96 percent down since the beginning of the trading day. The stock's last reported lowest price was 10.09. Altimmune has less than a 10 % chance of experiencing some financial distress in the next two years of operation, but has generated negative returns over the last 90 days. Equity ratings for Altimmune are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 17th of December 2020 and ending today, the 7th of December 2022. Click here to learn more.
CUSIP
42224H203
Fiscal Year End
December
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
6th of October 2005
Category
Healthcare
Classification
Health Care
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland. Altimmune operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 49.16 M outstanding shares of which 7.29 M shares are presently shorted by investors with about 6.22 days to cover. More on Altimmune

Moving against Altimmune

-0.6LLYEli Lilly And Sell-off TrendPairCorr
-0.54ABBVAbbVie Inc Sell-off TrendPairCorr
-0.51BMYBristol-Myers Squibb Aggressive PushPairCorr
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores

Altimmune Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Altimmune's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Altimmune or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Altimmune generated a negative expected return over the last 90 days
Altimmune has high historical volatility and very poor performance
The company reported the last year's revenue of 4.41 K. Reported Net Loss for the year was (97.09 K) with loss before taxes, overhead, and interest of (71.09 M).
Altimmune has about 184.76 M in cash with (78.24 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.81.
Altimmune has a frail financial position based on the latest SEC disclosures
Over 95.0% of the company shares are held by institutions such as insurance companies
Latest headline from news.google.com: Altimmune Weight Loss Data Signals A Costly Confusion - Seeking Alpha
New SymbolALT1
President CEO, DirectorWilliam Enright
Fama & French Classification
Average Analyst Recommendation
Analysts covering Altimmune report their recommendations after researching Altimmune's financial statements, talking to executives and customers, or listening in on Altimmune's conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Altimmune. The Altimmune consensus assessment is calculated by taking the average forecast from all of the analysts covering Altimmune.
Strong Buy6 Opinions
Piotroski F Score
Piotroski F-Score is a popular financial indicator that puts together nine criteria to evaluate the financial strength of Altimmune based on its profitability, leverage, liquidity, source of funds, and operating efficiency. It is an academic score (developed by Joseph Piotroski in 2002) to determine the current strength of Altimmune financial position. Scores of 8 and 9 are usually classified as strong value stocks, whereas scores of 2 or below are considered weak value stocks.
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares Diluted44.5 M41.3 M
Significantly Up
Increasing
Slightly volatile
Weighted Average Shares44.5 M41.3 M
Significantly Up
Increasing
Slightly volatile
Return on Average Assets(45.15)(41.8513)
Significantly Down
Increasing
Very volatile
Net Cash Flow from Operations(80.3 M)(78.2 M)
Fairly Down
Decreasing
Stable
Current Liabilities19.3 M18.3 M
Notably Up
Increasing
Very volatile
Total Liabilities21.7 M19.7 M
Significantly Up
Increasing
Very volatile
Gross Margin0.890.9
Fairly Down
Decreasing
Slightly volatile
Total Debt66.1 K64.4 K
Fairly Up
Decreasing
Slightly volatile
Asset Turnover0.01950.019
Fairly Up
Decreasing
Slightly volatile
Current Assets220.2 M204.1 M
Significantly Up
Increasing
Slightly volatile
Total Assets236.1 M218.9 M
Significantly Up
Increasing
Slightly volatile
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Altimmune's available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Strong HoldUndervalued
Financial Strength
Altimmune's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Altimmune's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Altimmune's financial leverage. It provides some insight into what part of Altimmune's total assets is financed by creditors.
Share Download
Share Download
By using current balance sheet information, investors can analyze the liability, assets, and equity on Altimmune's books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how Altimmune deploys its capital and how much of that capital is borrowed.
Liquidity
Altimmune cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company has 1.45 M in debt with debt to equity (D/E) ratio of 0.01, which may show that the company is not taking advantage of profits from borrowing. Altimmune has a current ratio of 13.84, demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due. Debt can assist Altimmune until it has trouble settling it off, either with new capital or with free cash flow. So, Altimmune's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Altimmune sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Altimmune to invest in growth at high rates of return. When we think about Altimmune's use of debt, we should always consider it together with cash and equity.

Operating Cash Flow

(80.3 Million)
Altimmune (ALT) is traded on NASDAQ Exchange in USA and employs 47 people. Altimmune is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a total capitalization of 521.09 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Altimmune's market, we take the total number of its shares issued and multiply it by Altimmune's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Altimmune runs under Biotechnology sector within Health Care industry. The entity has 49.16 M outstanding shares of which 7.29 M shares are presently shorted by investors with about 6.22 days to cover. Altimmune has about 184.76 M in cash with (78.24 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.81.
Check Altimmune Probability Of Bankruptcy
Ownership
Altimmune holds a total of fourty-nine million one hundred fifty-nine thousand one hundred outstanding shares. The majority of Altimmune outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Altimmune to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Altimmune. Please pay attention to any change in the institutional holdings of Altimmune as this could imply that something significant has changed or about to change at the company. Please note that no matter how much assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.

Ownership Allocation (%)

Check Altimmune Ownership Details

Altimmune Stock Price Odds Analysis

Attributed to a normal probability distribution, the odds of Altimmune jumping above the current price in 90 days from now is about 72.6%. The Altimmune probability density function shows the probability of Altimmune stock to fall within a particular range of prices over 90 days. Considering the 90-day investment horizon the stock has a beta coefficient of 1.7241. This suggests as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Altimmune will likely underperform. Additionally, the company has a negative alpha, implying that the risk taken by holding this instrument is not justified. Altimmune is significantly underperforming NYSE Composite.
  Odds Below 10.28HorizonTargetOdds Above 10.28
27.34%90 days
 10.28 
72.60%
Based on a normal probability distribution, the odds of Altimmune to move above the current price in 90 days from now is about 72.6 (This Altimmune probability density function shows the probability of Altimmune Stock to fall within a particular range of prices over 90 days) .

Altimmune Historical Income Statement

Altimmune Income Statement is one of the three primary financial statements used for reporting Altimmune's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Altimmune revenue and expense. Altimmune Income Statement primarily focuses on the company's revenues and expenses during a particular period.
Altimmune Gross Profit is comparatively stable at the moment as compared to the past year. Altimmune reported Gross Profit of 4.41 Million in 2021. Interest Expense is likely to gain to 5,805 in 2022, whereas Net Income is likely to drop (99.6 M) in 2022. View More Fundamentals

Altimmune Stock Against Markets

Picking the right benchmark for Altimmune stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Altimmune stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Altimmune is critical whether you are bullish or bearish towards Altimmune at a given time.
The entity Altimmune with a symbol ALT was recently relisted or delisted. You can potentially use ISHARES DIVERSIFIED ALTERNATIVES with a symbol ALT1. Please make sure the ticker renaming or change in the classification of Altimmune is not a temporary action by the exchange.

Altimmune Corporate Directors

Altimmune corporate directors refer to members of an Altimmune board of directors. The board of directors generally takes responsibility for the Altimmune's affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Altimmune's board members must vote for the resolution. The Altimmune board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.
Maurice Tchenio - Director - Permanent Representative of Apax PartnersProfile
Phuong Thai - Director of MarketingProfile
Carl Stubbings - Non-Executive DirectorProfile
Florence Parly - Independent DirectorProfile

Invested in Altimmune?

The danger of trading Altimmune is mainly related to its market volatility and company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Altimmune is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Altimmune. The Shape ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Altimmune is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Please continue to Trending Equities. You can also try Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.

Complementary Tools for analysis

When running Altimmune price analysis, check to measure Altimmune's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Altimmune is operating at the current time. Most of Altimmune's value examination focuses on studying past and present price action to predict the probability of Altimmune's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Altimmune's price. Additionally, you may evaluate how the addition of Altimmune to your portfolios can decrease your overall portfolio volatility.
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Go
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Go
Fund Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Go
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Go
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Go
Fundamental Analysis
View fundamental data based on most recent published financial statements
Go
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Go
Is Altimmune's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Altimmune. If investors know Altimmune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Altimmune listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
521.1 M
Quarterly Revenue Growth YOY
(0.99) 
Return On Assets
(0.23) 
Return On Equity
(0.42) 
The market value of Altimmune is measured differently than its book value, which is the value of Altimmune that is recorded on the company's balance sheet. Investors also form their own opinion of Altimmune's value that differs from its market value or its book value, called intrinsic value, which is Altimmune's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Altimmune's market value can be influenced by many factors that don't directly affect Altimmune's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Altimmune's value and its price as these two are different measures arrived at by different means. Investors typically determine Altimmune value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Altimmune's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.